Skip to main content

Table 3 Association with NT-proBNP and All-cause Mortality in Patients with Ischemic Heart Failure according to Diabetes Mellitus Status in Propensity-matched Cohort

From: Diabetes mellitus status modifies the association between N-terminal B-type natriuretic peptide and all-cause mortality risk in ischemic heart failure: a prospective cohort study

 

Overall

Without diabetes mellitus

With diabetes mellitus

P-interaction

NT-proBNP as continuous variable (Per 1-log NT-proBNP increment)

Event/Total (%)

315/1554 (20.3)

163/777 (21.0)

152/777 (19.6)

/

Incidence Rate (100 person-years)

6.3 (5.6-7.0)

6.5 (5.6–7.6)

6.1 (5.2–7.1)

/

Person-Year

4998

2494

2504

/

Model 1 (HR and 95% CI)

1.66 (1.51–1.81)

1.46 (1.29–1.65)

1.95 (1.69–2.24)

0.003

Model 2 (HR and 95% CI)

1.58 (1.43–1.75)

1.42 (1.25–1.63)

1.85 (1.58–2.15)

0.002

NT-proBNP as categorical variable

NT-proBNP categorization

NT-proBNP < 1800 pg/ml

NT-proBNP ≥ 1800 pg/ml

NT-proBNP < 1800 pg/ml

NT-proBNP ≥ 1800 pg/ml

NT-proBNP < 1800 pg/ml

NT-proBNP ≥ 1800 pg/ml

 

Event/Total (%)

107/876 (12.2)

208/678 (30.7)

64/431 (14.9)

99/346 (28.6)

43/445 (9.7)

109/332 (32.8)

/

Incidence Rate (100 person-years)

3.7 (3.0-4.4)

10.0 (8.7–11.5)

4.4 (3.5–5.7)

9.4 (7.7–11.4)

2.9 (2.2–3.9)

10.7 (8.8–12.9)

/

Person-Year

2922

2076

1440

1054

1482

1022

/

Model 1 (HR and 95% CI)

1.00 (Reference)

2.71 (2.14–3.42)

1.00 (Reference)

2.08 (1.52–2.85)

1.00 (Reference)

3.66 (2.57–5.21)

0.021

Model 2 (HR and 95% CI)

1.00 (Reference)

2.37 (1.85–3.03)

1.00 (Reference)

1.91 (1.36–2.67)

1.00 (Reference)

3.12 (2.15–4.53)

0.018

  1. Model 1 adjusted for none
  2. Model 2 adjusted for medications at discharge
  3. NT-proBNP, N-terminal pro-B-type natriuretic peptide